September 01, 2015

Not intended for U.S. and UK Media - Late-Breaking Science at ESC Congress 2015:

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer's Xarelto® in Patients with Non-Valvular Atrial Fibrillation

Insights from more than 45,000 real-world patients with atrial fibrillation (AF) confirm low bleeding rates for Xarelto / Late-breaking XANTUS study expands on ROCKET AF data, demonstrating Xarelto provides highly effective stroke prevention in both high- and lower-risk patients / Two-year findings from an ongoing post-marketing safety surveillance (PMSS) study show rates and patterns of major bleeding to be consistent with ROCKET AF
Berlin, September 1, 2015 - Bayer HealthCare and its development partner
Janssen Pharmaceuticals, Inc. today announced results from two real-world
studies, XANTUS and a post-marketing safety surveillance (PMSS) study, both
demonstrating that the rates of major bleeding in patients with atrial
fibrillation (AF) taking the oral Factor Xa inhibitor Xarelto® (rivaroxaban)
for stroke prevention were low in routine clinical practice and consistent with
findings from the Phase III ROCKET AF clinical trial. Results from the two
studies, which collectively included more than 45,000 patients from across
Europe, Canada and the U.S., were presented at ESC Congress 2015. The XANTUS
findings have also been accepted for publication in the European Heart Journal.

"Real-world evidence is increasingly important for physicians as it complements
and expands on what is already known from clinical trials," said XANTUS
Principal Investigator Professor A. John Camm, Professor of Clinical Cardiology
in the Cardiovascular and Cell Sciences Research Institute at St George's
University of London, UK. "XANTUS is a real-world study that does just that -
the findings demonstrate the safety and effectiveness of rivaroxaban across a
broader range of patients than included in the Phase III trial, specifically
those at lower risk of stroke yet still in need of anticoagulation therapy.
XANTUS gives physicians reassurance to prescribe rivaroxaban as an effective
and generally well-tolerated treatment option for both their high- and
lower-risk patients with AF."

XANTUS, the first international, prospective real-world evidence study in
patients with AF with a non-vitamin K antagonist oral anticoagulant (NOAC),
reaffirms the positive benefit-risk profile of Xarelto for stroke prevention in
patients with AF. This was first demonstrated in the Phase III clinical trial
ROCKET AF, in which Xarelto was shown to be associated with a similar overall
bleeding profile compared to warfarin with significantly lower rates of the
most feared bleeding events such as intracranial and fatal bleeds, but with a
significant increase in gastrointestinal bleeds. While patients in ROCKET AF
were moderate to high risk with a mean CHADS score of 3.5, patients studied in XANTUS had
a lower average risk of stroke, with a mean CHADS score of 2.0. The incidence of major
bleeding in patients taking rivaroxaban was 3.6 per 100 person-years in ROCKET
AF. In XANTUS, the incidence of major bleeding associated with rivaroxaban was
2.1 per 100 person-years. Additionally, the findings from the 39,052-patient
PMSS study further confirm the favourable safety profile of rivaroxaban with an
incidence of major bleeding of 2.9 per 100 person-years.

"Bayer is committed to supporting physicians and patients in the safe and
responsible use of Xarelto," said Dr Michael Devoy, Member of the Bayer
HealthCare Executive Committee and Chief Medical Officer of Bayer HealthCare.
"And as part of that commitment, these studies are invaluable as the real-world
insights help physicians make more informed treatment decisions in the
management of AF for the various types of patients that they see in daily
clinical practice."

XANTUS and the PMSS study are part of the extensive evaluation of rivaroxaban -
both completed and ongoing - that will include more than 275,000 patients in
clinical trials and real-world settings.

About XANTUS

XANTUS is an international, prospective, single-arm, observational study
designed by Bayer HealthCare and in agreement with the European Medicines
Agency (EMA) to evaluate the safety and effectiveness of rivaroxaban for stroke
prevention in 6,784 patients with non-valvular AF from 311 centres across
Europe, Canada and Israel in routine clinical practice. All treatment and
dosing decisions were at the discretion of the treating physicians and patients
were followed up for one year or until 30 days after premature discontinuation.
Bleeding events and major thromboembolic events were centrally adjudicated by
an independent committee. By the end of the observation period the majority
(96.1%) of patients had not experienced treatment-emergent major bleeding,
all-cause death or stroke / systemic embolism. Rates for on-treatment all-cause
mortality were 1.9 events per 100 person-years. Overall, patients experienced
treatment-emergent major bleeding at a rate of 2.1 events per 100 person-years;
most of these major bleeds were treated using standard clinical measures. Rates
of fatal bleeding were 0.2 events per 100 person-years. Critical organ bleeding
occurred at a rate of 0.7 events per 100 person-years, which included
intracranial haemorrhage (ICH) at a rate of 0.4 events per 100 person-years.
Stroke occurred at a rate of 0.7 events per 100-person-years. 75.1% of patients
reported to their physician that they were 'very satisfied' or 'satisfied' with
their treatment.

About the PMSS Study

PMSS is an ongoing, five-year, retrospective, observational U.S. study designed
by Janssen in conjunction with the U.S. Department of Defense (DoD) and Health
ResearchTx LLC (HRTX), and in agreement with the U.S. Food and Drug
Administration (FDA) as part of a post-marketing requirement, to analyse and
report major bleeding events, associated risk factors and bleeding-related
clinical outcomes in patients with non-valvular AF taking rivaroxaban.
Researchers analysed data from January 1, 2013 to December 31, 2014 using DoD
integrated electronic healthcare records. Major bleeding cases were ascertained
using a validated Cunningham (2011) algorithm, which was generally consistent
with, but not identical to the definition of major bleeding used in clinical
studies, because it relied on retrospectively identified electronic medical
records.

About Xarelto® (Rivaroxaban)

Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral
anticoagulant (NOAC) and is marketed under the brand name Xarelto®. Xarelto is
approved for seven indications, protecting patients across more venous and
arterial thromboembolic (VAT) conditions than any other NOAC:

- The prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation (AF) with one or more risk factors

- The treatment of deep vein thrombosis (DVT) in adults

- The treatment of pulmonary embolism (PE) in adults

- The prevention of recurrent DVT and PE in adults

- The prevention of venous thromboembolism (VTE) in adult patients undergoing
elective hip replacement surgery

- The prevention of VTE in adult patients undergoing elective knee replacement
surgery

- The prevention of atherothrombotic events (cardiovascular death, myocardial
infarction or stroke) after an Acute Coronary Syndrome in adult patients with
elevated cardiac biomarkers and no prior stroke or transient ischaemic attack
(TIA) when co-administered with acetylsalicylic acid (ASA) alone or with ASA
plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications
Xarelto is approved in more than 130 countries.

Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed
with Janssen Research & Development, LLC. Xarelto is marketed outside the U.S.
by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (Janssen
Research & Development, LLC and Janssen Pharmaceuticals, Inc. are part of the
Janssen Pharmaceutical Companies of Johnson & Johnson.).

Anticoagulant medicines are potent therapies used to prevent or treat serious
illnesses and potentially life-threatening conditions. Before initiating
therapy with anticoagulant medicines, physicians should carefully assess the
benefit and risk for the individual patient.

Responsible use of Xarelto is a very high priority for Bayer, and the company
has developed a Prescribers Guide for physicians and a Xarelto Patient Card for
patients to support best practice.

To learn more, please visit https://prescribe.xarelto.com
To learn more about thrombosis, please visit www.thrombosisadviser.com
To learn more about Xarelto, please visit www.xarelto.com

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the
world's leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31,
2014) and is represented in more than 100 countries. More information is
available at www.healthcare.bayer.com.

Our online press service is just a click away: press.healthcare.bayer.com

Find more information at www.bayerpharma.com.

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.